All Oncology News

Jonathan E. Rosenberg, MD, discusses the promise of enfortumab vedotin in patients with bladder cancer who previously received a checkpoint inhibitor, and reflects on the rapid pace of change in the urothelial cancer landscape.

Mario Sznol, MD, discusses the latest developments with immunotherapy in metastatic renal cell carcinoma.

The National Heart, Lung and Blood Institute, part of the National Institutes of Health, awarded a $4.7 million grant to Cleveland Clinic to study the prevention of life-threatening, cancer-associated blood clots.

Noa Biran, MD, discusses patient-reported outcomes following autologous stem cell transplant in patients with myeloma.

The FDA has approved mogamulizumab for the treatment of patients with cutaneous T-cell lymphoma who have received at least 1 prior systemic therapy.

Daniel J. George, MD, discusses the findings from Abi Race and the implications they have on clinical trials in prostate cancer moving forward.

Manish A. Shah, MD, shares insight on the challenges that remain in the treatment of esophageal and gastric cancers.

Naamit K. Gerber, MD, discusses recent advances in radiation therapy in the field of breast cancer.

A rolling submission of an FDA new drug application has been completed for selinexor for the treatment of patients with penta-refractory multiple myeloma, according to Karyopharm Therapeutics.

In combination with weekly paclitaxel, tumor treating fields, an antimitotic therapy that delivers continuous low-intensity electrical fields to the tumor region, has been found safe in platinum-resistant ovarian cancer.

David M. Kurtz, MD, PhD, discusses the clinical use of circulating tumor DNA in lymphoma.

The FDA has granted a breakthrough therapy designation to the combination of encorafenib (Braftovi), binimetinib (Mektovi), and cetuximab (Erbitux) for the treatment of patients with BRAF V600E–mutant metastatic colorectal cancer.

The FDA has granted lurbinectedin (PM1183) an orphan drug designation for the treatment of patients with small cell lung cancer.

Suman Kambhampati, MD, discusses some of the latest developments in the treatment of patients with relapsed/refractory multiple myeloma.

Susanna Ulahannan, MD, highlights trials from the 2018 ASCO Annual Meeting across gastrointestinal malignancies and future therapeutic approaches across the landscape.

Jianyu Rao, MD, discusses the evolution of pathology in gynecologic cancers.

Hossein Borghaei, DO, MS, discusses the results of the subgroup analysis of the ongoing CheckMate-227 trial in metastatic non–small cell lung cancer.

Sara A. Hurvitz, MD, discussed targeted therapy advancements, the rise of trastuzumab biosimilars, and the future of HER2-positive breast cancer treatment.

Robert L. Talley, MD, elaborates on the clinical trial findings that are shifting standards of care in chronic leukemias.

Guadecitabine (SGI-110) did not meet the coprimary endpoints of the phase III ASTRAL-1 study comparing the hypomethylating agent with physician’s choice of standard therapy in treatment-naïve adult patients with AML.

Denise A. Yardley, MD, weighs in on the recent data reported in breast cancer.

Noopur Raje, MD, discusses the updated results from the CRB-401 trial and next steps with bb2121 in multiple myeloma.

Shilpa Gupta, MD, discusses the tolerability and safety of pembrolizumab and bevacizumab in renal cell carcinoma, as well as the future of bladder cancer treatment in the neoadjuvant setting.

The FDA has granted a breakthrough therapy designation to the combination of lenvatinib (Lenvima) and pembrolizumab (Keytruda) for the treatment of patients with advanced and/or metastatic non–microsatellite instability high/proficient mismatch repair endometrial carcinoma who have progressed after ≥1 prior systemic therapy.

The FDA has granted a breakthrough therapy designation to quizartinib for the treatment of adult patients with relapsed/refractory FLT3-ITD–positive acute myeloid leukemia.

PF-05280014 (Trazimera), a biosimilar for trastuzumab (Herceptin), has been approved for use in the European Union to treat patients with HER2 overexpressing metastatic or early breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

The European Commission has approved nivolumab (Opdivo) as an adjuvant treatment for adult patients with completely resected melanoma with lymph node involvement or metastatic disease, regardless of BRAF mutation status.

The FDA has approved iobenguane I-131 (Azedra) for adult and pediatric patients aged ≥12 years with iobenguane scan–positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of pembrolizumab (Keytruda) for the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma who progressed following platinum-based chemotherapy and have a PD-L1 tumor proportion score ≥50%.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of frontline pembrolizumab (Keytruda) for use in combination with standard chemotherapy for patients with metastatic nonsquamous non–small cell lung cancer without EGFR or ALK mutations, regardless of PD-L1 expression.